Table 2 Pharmacodynamic parameters based on anti-Xa measurements * after subcutaneous administration in 20 healthy volunteers
|  | Average MW | Mna | Dose | t½ | Renal clearance | Total clearanceb |
|---|---|---|---|---|---|---|
(Da) | (Da) | (IU) | (h) | (% of dose) | (mL/min) | |
Enoxaparin | 4,400 | 3,100 | 2,000 | 3.95 ± 0.65 | 6.4 ± 6.5 | 16.67 ± 5.50 |
4,000 | 4.37 ± 0.47 | 8.7 ± 3.4 | 13.83 ± 3.17 | |||
Nadroparin | 4,400 | 3,700 | 3,075 | 3.74 ± 0.68 | 3.9 ± 1.8 | 21.50 ± 7.00 |
Dalteparin | 5,700 | 4,750 | 2,500 | 2.81 ± 0.84 | 3.4 ± 1.5 | 33.33 ± 11.83 |